Macrophage migration inhibitory factor deficiency ameliorates high-fat diet induced insulin resistance in mice with reduced adipose inflammation and hepatic steatosis

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Finucane, Orla M ^a,b   Reynolds, Clare M ^b,c   McGillicuddy, Fiona C ^b   Harford, Karen A ^b   Morrison, Martine ^b   Baugh, John ^b   Roche, Helen M ^b  

^a ST JAMES S HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CD74 ANTIGEN; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; MESSENGER RNA; MIGRATION INHIBITION FACTOR; PROTEIN KINASE B; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ISOMERASE; MACROPHAGE MIGRATION INHIBITION FACTOR; MIF PROTEIN, MOUSE;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; CYTOKINE RELEASE; FATTY LIVER; FOOD INTAKE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; IMMUNOPHENOTYPING; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MOUSE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; 3T3 CELL LINE; ADVERSE EFFECTS; ANIMAL; CHEMICALLY INDUCED; CYTOLOGY; DEFICIENCY; EATING; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM;

MUS;

3T3 CELLS; ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; DIET, HIGH-FAT; EATING; FATTY LIVER; INFLAMMATION; INSULIN RESISTANCE; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MACROPHAGES; MICE; OBESITY;

EID: 84912062050     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113369     Document Type: Article

References (51)

1. Hotamisligil GS (2003) Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 27 Suppl 3: S53-55.
2. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116: 1793-1801.
3. Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest 121: 2111-2117.
4. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808.
5. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830.
6. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
7. Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969.
8. Morris DL, Singer K, Lumeng CN (2011) Adipose tissue macrophages: phenotypic plasticity and diversity in lean and obese states. Curr Opin Clin Nutr Metab Care 14: 341-346.
9. Lumeng CN, Bodzin JL, Saltiel AR (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117: 175-184.
10. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259: 87-91.
11. Solinas G, Vilcu C, Neels JG, Bandyopadhyay GK, Luo JL, et al. (2007) JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab 6: 386-397.
12. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, et al. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116: 1494-1505.
13. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, et al. (2006) CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116: 115-124.
14. Kamei N, Tobe K, Suzuki R, Ohsugi M, Watanabe T, et al. (2006) Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281: 26602-26614.
15. Rull A, Camps J, Alonso-Villaverde C, Joven J (2010) Insulin resistance, inflammation, and obesity: role of monocyte chemoattractant protein-1 (or CCL2) in the regulation of metabolism. Mediators Inflamm 2010: 1-11.
16. Chen A, Mumick S, Zhang C, Lamb J, Dai H, et al. (2005) Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes Res 13: 1311-1320.
17. Inouye KE, Shi H, Howard JK, Daly CH, Lord GM, et al. (2007) Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 56: 2242-2250.
18. Chavey C, Fajas L (2009) CXCL5 drives obesity to diabetes, and further. Aging (Albany NY) 1: 674-677.
19. Straczkowski M, Dzienis-Straczkowska S, Stepien A, Kowalska I, Szelachowska M, et al. (2002) Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metab 87: 4602-4606.
20. Shah R, Hinkle CC, Ferguson JF, Mehta NN, Li M, et al. (2011) Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes 60: 1512-1518.
21. Baugh JA, Bucala R (2002) Macrophage migration inhibitory factor. Crit Care Med 30: S27-35.
22. Finucane OM, Reynolds CM, McGillicuddy FC and Roche HM (2012) Insights into the role of macrophage migration inhibitory factor in obesity and insulin resistance. Proc Nutr Soc 71: 622-633.
23. Vozarova B, Stefan N, Hanson R, Lindsay RS, Bogardus C, et al. (2002) Plasma concentrations of macrophage migration inhibitory factor are elevated in Pima Indians compared to Caucasians and are associated with insulin resistance. Diabetologia 45: 1739-1741.
24. Skurk T, Herder C, Kraft I, Muller-Scholze S, Hauner H, et al. (2005) Production and release of macrophage migration inhibitory factor from human adipocytes. Endocrinology 146: 1006-1011.
25. Herder C, Illig T, Baumert J, Muller M, Klopp N, et al. (2008) Macrophage migration inhibitory factor (MIF) and risk for coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Atherosclerosis 200: 380-388.
26. Church TS, Willis MS, Priest EL, Lamonte MJ, Earnest CP, et al. (2005) Obesity, macrophage migration inhibitory factor, and weight loss. Int J Obes (Lond) 29: 675-681.
27. Dandona P, Aljada A, Ghanim H, Mohanty P, Tripathy C, et al. (2004) Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 89: 5043-5047.
28. Hirokawa J, Sakaue S, Tagami S, Kawakami Y, Sakai M, et al. (1997) Identification of macrophage migration inhibitory factor in adipose tissue and its induction by tumor necrosis factor-alpha. Biochem Biophys Res Commun 235: 94-98.
29. Hirokawa J, Sakaue S, Furuya Y, Ishii J, Hasegawa A, et al. (1998) Tumor necrosis factor-alpha regulates the gene expression of macrophage migration inhibitory factor through tyrosine kinase-dependent pathway in 3T3-L1 adipocytes. J Biochem 123: 733-739.
30. Sakaue S, Nishihira J, Hirokawa J, Yoshimura H, Honda T, et al. (1999) Regulation of macrophage migration inhibitory factor (MIF) expression by glucose and insulin in adipocytes in vitro. Mol Med 5: 361-371.
31. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, et al. (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13: 587-596.
32. Verschuren L, Kooistra T, Bernhagen J, Voshol PJ, Ouwens DM, et al. (2009) MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ Res 105: 99-107.
33. Atsumi T, Cho YR, Leng L, McDonald C, Yu T, et al. (2007) The proinflammatory cytokine macrophage migration inhibitory factor regulates glucose metabolism during systemic inflammation. J Immunol 179: 5399-5406.
34. Al-Abed Y, Metz CN, Cheng KF, Aljabari B, VanPatten S, et al. (2011) Thyroxine is a potential endogenous antagonist of macrophage migration inhibitory factor (MIF) activity. Proc Natl Acad Sci U S A 108: 8224-8227.
35. Cvetkovic I, Al-Abed Y, Miljkovic D, Maksimovic-Ivanic D, Roth J, et al. (2005) Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 146: 2942-2951.
36. Waeber G, Calandra T, Roduit R, Haefliger JA, Bonny C, et al. (1997) Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. Proc Natl Acad Sci U S A 94: 4782-4787.
37. Toso C, Emamaullee JA, Merani S, Shapiro AM (2008) The role of macrophage migration inhibitory factor on glucose metabolism and diabetes. Diabetologia 51: 1937-1946.
38. Serre-Beinier V, Toso C, Morel P, Gonelle-Gispert C, Veyrat-Durebex C, et al. (2011) Macrophage migration inhibitory factor deficiency leads to agedependent impairment of glucose homeostasis in mice. J Endocrinol 206: 297-306.
39. Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395: 763-770.
40. Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, et al. (2008) Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab 8: 301-309.
41. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, et al. (2007) Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447: 1116-1120.
42. Lin X, Sakuragi T, Metz CN, Ojamaa K, Skopicki HA, et al. (2005) Macrophage migration inhibitory factor within the alveolar spaces induces changes in the heart during late experimental sepsis. Shock 24: 556-563.
43. McGillicuddy FC, Harford KA, Reynolds CM, Oliver E, Claessens M, et al. (2011) Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat dietinduced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes 60: 1688-1698.
44. Roger T, Froidevaux C, Martin C, Calandra T (2003) Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of Toll-like receptor 4 (TLR4). J Endotoxin Res 9: 119-123.
45. Roger T, David J, Glauser MP, Calandra T (2001) MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414: 920-924.
46. Saksida T, Stosic-Grujicic S, Timotijevic G, Sandler S, Stojanovic I (2012) Macrophage migration inhibitory factor deficiency protects pancreatic islets from palmitic acid-induced apoptosis. Immunol Cell Biol 90: 688-698.
47. Bacher M, Meinhardt A, Lan HY, Mu W, Metz CN, et al. (1997) Migration inhibitory factor expression in experimentally induced endotoxemia. Am J - Pathol 150: 235-246.
48. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, et al. (1999) Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189: 341-346.
49. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, et al. (2002) A central role for JNK in obesity and insulin resistance. Nature 420: 333-336.
50. Utzschneider KM, Kahn SE (2006) Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 91: 4753-4761.
51. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, et al. (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46: 459-469.